Literature DB >> 15576152

Tissue response to partially in vitro predegraded poly-L-lactide implants.

Wim H De Jong1, J Eelco Bergsma, Joke E Robinson, Ruud R M Bos.   

Abstract

The in vivo local reaction of as-polymerized poly-L-lactide composed of 96% L-lactide and 4% D-lactide (PLA96) was investigated by histology at 2, 13 and 26 weeks after subcutaneous implantation in rats. In order to simulate possible end stage reactions the PLA96 was also predegraded in vitro until approximately 50% weight loss. The local reaction of predegraded PLA (PLA96(168)) was compared to the local reaction of polyethylene (PE) and non-predegraded PLA (PLA96). For PE and PLA96 a mild local reaction was observed at all time points consisting of a minimal layer of macrophage like cells with incidentally multinucleated giant cells at the implant interface, surrounded by a mild connective tissue capsule. For PLA96 at weeks 13 and 26 some minimal alterations in terms of degradation and ingrowth of cells was noted. The in vitro incubation (90 degrees C for 168 h) of PLA96(168) resulted for the thin 0.2 mm samples in complete degradation. Predegraded 0.5, 1.0 and 2.0 mm PLA96(168) samples were implanted and evaluated. The 1.0 and 2.0 mm samples could be evaluated for all time points investigated, but some 0.5 mm PLA96(168) samples were already completely resorbed at week 2 after implantation. In general, responses found for the predegraded PLA96(168) at weeks 2, 13 and 26 were similar with a pronounced macrophage infiltrate containing birefringent material, encapsulation of polymer fragments, and the presence of a debris area consisting of polymer and cellular remnants. In lymph nodes foamy macrophages with birefringent material were only observed in lymph nodes draining sites with predegraded PLA96(168). Immunohistochemistry was performed for further characterization of the cellular infiltrate. At the implant interface of the non-degrading PE and PLA96, ED1 and OX6 (MHC class II) positive cells were identified. In the capsule macrophage like cells expressed all three macrophage markers ED1, ED2, and ED3. CD4 and CD8 positive cells, indicating T helper and T supressor/cytotoxic cells, respectively, could be observed in low numbers, CD4 more than CD8. Both CD4 and CD8 were occasionally observed within the degrading PLA96(168) implant. Polymorphonuclear neutrophilic granulocytes were mainly observed at 2 weeks after implantation. We showed that predegradation could be used as a means to study late tissue reactions to polymers. Complete degradation may be studied with relatively thin implants, but this may lead to rather optimistic interpretation of resorption periods. When materials are intended to be used for screws and/or plates for bone fixation, implants of at least 1.0-2.0 mm thickness should be used as these may show a more realistic representation of the resorption characteristics of the material under investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15576152     DOI: 10.1016/j.biomaterials.2004.06.026

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  17 in total

1.  Review and Evaluation of Treatment Procedures Using Injectable Poly-L-Lactic Acid in the Treatment of Human Immunodeficiency Virus-associated Facial Lipoatrophy.

Authors:  Douglas Mest; Gail Humble
Journal:  J Clin Aesthet Dermatol       Date:  2010-12

2.  Gradual pore formation in natural origin scaffolds throughout subcutaneous implantation.

Authors:  Ana M Martins; James D Kretlow; Ana R Costa-Pinto; Patrícia B Malafaya; Emanuel M Fernandes; Nuno M Neves; Catarina M Alves; Antonios G Mikos; F Kurtis Kasper; Rui L Reis
Journal:  J Biomed Mater Res A       Date:  2011-12-30       Impact factor: 4.396

3.  Crystallinity assessment and in vitro cytotoxicity of polylactide scaffolds for biomedical applications.

Authors:  J R Sarasua; N López-Rodríguez; E Zuza; S Petisco; B Castro; M del Olmo; T Palomares; A Alonso-Varona
Journal:  J Mater Sci Mater Med       Date:  2011-08-21       Impact factor: 3.896

4.  [New developments in drug-eluting stents].

Authors:  M Kollum; C Bode
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

5.  Dual Extrusion Patterning Drives Tissue Development Aesthetics and Shape Retention in 3D Printed Nipple-Areola Constructs.

Authors:  Sarah Van Belleghem; Bhushan Mahadik; Kirstie Snodderly; Zoe Mote; Bin Jiang; Justine R Yu; Shannon McLoughlin; Xiaoming He; Arthur J Nam; John P Fisher
Journal:  Adv Healthc Mater       Date:  2021-10-19       Impact factor: 9.933

6.  Differential degradation rate and underlying mechanism of a collagen/chitosan complex in subcutis, spinal cord and brain tissues of rat.

Authors:  Feng Fu; Xiang Zhu; Zhe Qin; Jing-Jing Wang; Chao Xu; Li-Na Wang; Yue Tu; Sai Zhang; Rui-Xin Li; Xiao-Hong Li; Ming-Liang Zhao
Journal:  J Mater Sci Mater Med       Date:  2018-03-19       Impact factor: 3.896

7.  Local foreign-body reaction to commercial biodegradable implants: an in vivo animal study.

Authors:  Amy S Xue; John C Koshy; William M Weathers; Erik M Wolfswinkel; Yoav Kaufman; Safa E Sharabi; Rodger H Brown; M John Hicks; Larry H Hollier
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-01-09

8.  In vivo bone biocompatibility and degradation of porous fumarate-based polymer/alumoxane nanocomposites for bone tissue engineering.

Authors:  Amit S Mistry; Quynh P Pham; Corinne Schouten; Tiffany Yeh; Elizabeth M Christenson; Antonios G Mikos; John A Jansen
Journal:  J Biomed Mater Res A       Date:  2010-02       Impact factor: 4.396

9.  Bioabsorbable vs. titanium screws for first tarsometatarsal joint arthrodesis: An in-vitro study.

Authors:  Nikke Partio; Ville M Mattila; Heikki Mäenpää
Journal:  J Clin Orthop Trauma       Date:  2019-08-28

10.  The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells.

Authors:  Emma Luong-Van; Lisbeth Grøndahl; Shujun Song; Victor Nurcombe; Simon Cool
Journal:  J Mol Histol       Date:  2007-08-11       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.